LAVA Therapeutics NV Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q4 FY2021 As of Dec 31, 2021
Property and equipment, net
Right-of-use assets
Other non-current assets and security deposits
Total non-current assets
Receivables and other
Prepaid expenses and other current assets
VAT receivable
Investments
Cash and cash equivalents
Total current assets
Total assets
Share capital
Equity-settled employee benefits reserve
Foreign currency translation reserve
Additional paid-in capital
Accumulated deficit
Total equity
Deferred revenue
Lease liabilities
Total non-current liabilities
Trade payables and other
VAT payable
Borrowings
License liabilities
Accrued expenses and other current liabilities
Total current liabilities
Total liabilities
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Prepaid expenses
Other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Other non-current assets
Total assets
Liabilities and shareholders' equity
Current liabilities:
Accounts payable
Accrued expenses and other current liabilities
Borrowings
Current portion of operating lease liabilities
Total current liabilities
Non-current portion of deferred revenue
Non-current portion of operating lease liabilities
Total liabilities
Shareholders' equity:
Common shares, $0.14 par value; 90,000,000 shares authorized as of September 30,2025, and December 31, 2024; 26,305,295 shares issued and outstanding as of September 30,2025, and December 31, 2024
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Total shareholders' equity
Total liabilities and shareholders' equity

Comments